homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Company profile
Ticker
QTTB
Exchange
Website
CEO
Arthur Tzianabos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Q32 Bio Securities Corp. • Q32 Bio Australia Pty Ltd • Q32 Bio Operations Inc. ...
QTTB stock data
Latest filings (excl ownership)
S-1
IPO registration
19 Apr 24
10-K/A
2023 FY
Annual report (amended)
12 Apr 24
8-K
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
26 Mar 24
8-K/A
Other Events
22 Mar 24
8-K
Other Events
20 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Mar 24
POS EX
Additional exhibits for listing
13 Mar 24
424B3
Prospectus supplement
13 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
425
Business combination disclosure
11 Mar 24
Latest ownership filings
SC 13D
ACORN BIOVENTURES, L.P.
4 Apr 24
SC 13D
Atlas Venture Fund X, L.P.
1 Apr 24
SC 13G
Carlyle Group Inc.
29 Mar 24
SC 13D
ORBIMED ADVISORS LLC
28 Mar 24
4
ARTHUR TZIANABOS
27 Mar 24
4
Isaac Manke
27 Mar 24
4
Mark T Iwicki
27 Mar 24
4
DAVID S. GRAYZEL
27 Mar 24
4
Diyong Xu
27 Mar 24
4
Jason Campagna
27 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.11 mm | 29.11 mm | 29.11 mm | 29.11 mm | 29.11 mm | 29.11 mm |
Cash burn (monthly) | 15.90 mm | 1.17 mm | 10.33 mm | 10.32 mm | 8.31 mm | 8.49 mm |
Cash used (since last report) | 107.93 mm | 7.95 mm | 70.16 mm | 70.06 mm | 56.45 mm | 57.63 mm |
Cash remaining | -78.82 mm | 21.16 mm | -41.05 mm | -40.95 mm | -27.34 mm | -28.52 mm |
Runway (months of cash) | -5.0 | 18.1 | -4.0 | -4.0 | -3.3 | -3.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 6 |
Closed positions | 7 |
Increased positions | 4 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 20.11 bn |
Total shares | 29.05 mm |
Total puts | 100.00 |
Total calls | 40.00 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Temasek | 5.65 mm | $6.61 bn |
PFE Pfizer | 5.00 mm | $48.05 mm |
5AM Ventures IV | 4.54 mm | $51.21 mm |
5AM Venture Management | 4.54 mm | $5.31 bn |
Flynn James E | 2.25 mm | $29.76 mm |
Vanguard | 2.05 mm | $2.39 bn |
BLK Blackrock | 1.11 mm | $1.29 bn |
Citadel Advisors | 879.11 k | $1.03 bn |
Vivo Capital | 370.07 k | $432.98 mm |
Geode Capital Management | 323.46 k | $378.54 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Paul Alloway | Common Stock | Option exercise | Acquire M | No | No | 0 | 23,530 | 0.00 | 51,566 |
25 Mar 24 | Paul Alloway | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 18,090 | 0.00 | 0 |
25 Mar 24 | Paul Alloway | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,440 | 0.00 | 0 |
25 Mar 24 | Charles Michaud Jr | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,448 | 0.00 | 18,046 |
25 Mar 24 | Charles Michaud Jr | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,360 | 0.00 | 0 |
25 Mar 24 | Charles Michaud Jr | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,088 | 0.00 | 0 |
News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
12 Apr 24
Oppenheimer Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $50
11 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 Apr 24
Piper Sandler Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $45
2 Apr 24
Press releases
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
3 Apr 24
Homology Medicines Declares Distribution to Common Stockholders
18 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, SCTL, FIXX, GRPH
1 Mar 24
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
1 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX
27 Feb 24